Graig Suvannavejh: Thank you for taking my question.
Adrian Rawcliffe: Thanks, Graig.
Operator: [Operator Instructions] Our next question comes from Peter Lawson of Barclays. Please go ahead.
Unidentified Analyst: Good morning. This is [Indiscernible] for Peter Lawson. Thank you for taking our question. And just to touch a little bit more on the Afamicel launch in 3Q, I believe you’ve highlighted that you’ll be focusing on 6 to 10 treatment centers in the beginning. Can you maybe add a little color for how you’re expecting to scale up to the 30 additional treatment centers and how long that might take? And if you’re expecting any kind of bolus of onboarding of patients in 3Q? Thank you so much.
Adrian Rawcliffe: Thanks. So yes, we anticipate that the first wave of treatment centers will be up and running within that launch window 6 to 10 within that launch window, and then expanding quite rapidly. We anticipate that we will be at up to 30 centers within the first two years of following launch. Those treatment centers, the initial ones are almost exclusively major sarcoma centers. They are all major sarcoma centers. They are obviously therefore major treatment centers and they have deep experience of cell therapy. They almost all also have a lot of experience of working with Afamicel and as we roll out to the 30 top centers, since we have been conducting our clinical trials and GSK was conducting the clinical trials for Letecel in major sarcoma centers.
There’s obviously going to be a large overlap between the clinical trial footprint for those two products and these centers. That has the advantage that the physicians know and understand Afamicel well, having utilized it in clinical trials, that they’re well used to cell therapy, and that they are indeed the major treatment centers, the top tier of the sarcoma Centers of Excellence. Does that answer the question, I think. Any further questions?
Operator: This concludes the question-and-answer session. I would like to turn the conference back over to Adrian Rawcliffe for any closing remarks.
Adrian Rawcliffe: Thank you. And thanks everybody for being on the call and thanks for your questions. We’re excited to have come this far in 2023. We look forward in 2024 to our first commercial approval and launch. And we’ll be updating you as we go through the year, starting, I think, with our Investor Day on the 18th of April at our Navy Yard facility in Philadelphia. And we look forward to seeing as many of you there as possible. Take care.
Operator: This concludes today’s conference call. You may disconnect your lines. Thank you for participating and have a pleasant day.
